Boceprevir (BOC)

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Chronic Hepatitis CHIV InfectionsHepatitis CHepatitis C, Chronic

Phase 2

Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)

CompletedNCT00160251

Merck Sharp & Dohme LLCChronic Hepatitis C

Start: 2005-09-30End: 2007-07-31Updated: 2015-10-14

Phase 3

Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)

CompletedNCT01390844

Merck Sharp & Dohme LLCHepatitis C, Chronic

Start: 2011-10-21End: 2015-06-19Updated: 2018-09-11

Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

CompletedNCT01482767

National Institute of Allergy and Infectious Diseases (NIAID)Hepatitis C, HIV Infections

Start: 2012-04-30End: 2015-04-30Updated: 2021-11-04